Table 1.
Baseline characteristics of patients with primary systemic vasculitis or polymyalgia rheumatica at the time of COVID-19 onset
| All patients (n=1202) | ||
|---|---|---|
| Mean age, years | 63·8 (17·1) | |
| Sex | ||
| Female | 733 (61·0%) | |
| Male | 469 (39·0%) | |
| Race or ethnicity | ||
| White | 724 (60·2%) | |
| Black | 19 (1·6%) | |
| Latin American | 145 (12·1%) | |
| Other | 110 (9·2%) | |
| Missing | 204 (17·0%) | |
| Region | ||
| Europe | 704 (58·6%) | |
| North America | 328 (27·3%) | |
| South America | 90 (7·5%) | |
| Other | 80 (6·7%) | |
| Time period | ||
| June 15, 2020, or before | 502 (41·8%) | |
| June 16, 2020, to Sept 30, 2020 | 164 (13·6%) | |
| Oct 1, 2020, to April 12, 2021 | 536 (44·6%) | |
| Diagnosis | ||
| ANCA-associated vasculitis | 353 (29·4%) | |
| Giant cell arteritis | 183 (15·2%) | |
| Polymyalgia rheumatica | 374 (31·1%) | |
| Behçet's syndrome | 112 (9·3%) | |
| Other vasculitis | 180 (15·0%) | |
| Number of comorbidities | ||
| 0 | 428 (35·6%) | |
| 1 | 388 (32·3%) | |
| ≥2 | 386 (32·1%) | |
| Comorbidities | ||
| Hypertension | 564 (46·9%) | |
| Cardiovascular disease | 222 (18·5%) | |
| Diabetes | 216 (18·0%) | |
| Chronic kidney disease | 160 (13·3%) | |
| Lung disease* | 212 (17·6%) | |
| Interstitial lung disease | 44 (3·7%) | |
| Cancer | 77 (6·4%) | |
| Body-mass index ≥30 mg/kg2 | 240 (20·0%) | |
| Smoking status | ||
| Ever smoker | 265 (22·0%) | |
| Never smoker | 448 (37·3%) | |
| Missing | 489 (40·7%) | |
| Median glucocorticoid dose, mg/day† | 6·0 (5·0–12·0) | |
| Categorical glucocorticoid (prednisolone equivalent) dose, mg/day | ||
| 0 | 369 (30·7%) | |
| 1–5 | 367 (30·5%) | |
| 6–9 | 99 (8·2%) | |
| ≥10 | 286 (23·8%) | |
| Missing | 81 (6·7%) | |
| Disease activity | ||
| Remission | 442 (36·8%) | |
| Low | 370 (30·8%) | |
| Moderate | 112 (9·3%) | |
| High or severe | 54 (4·5%) | |
| Missing | 224 (18·6%) | |
| Medication | ||
| No DMARDs | 571 (47·5%) | |
| Conventional synthetic DMARDs only | 367 (30·5%) | |
| Biological or targeted synthetic DMARDs only | 193 (16·1%) | |
| Combined biological or targeted synthetic plus conventional synthetic DMARDs | 71 (5·9%) | |
| Rituximab only‡ | 128/353 (36·3%) | |
| Cyclophosphamide only | 20 (1·7%) | |
Data are mean (SD), n (%), median (IQR), or n/N (%). ANCA=antineutrophil cytoplasmic antibody. DMARD=disease-modifying antirheumatic drug.
*
Includes interstitial lung disease, chronic obstructive pulmonary disease, asthma, or other lung diseases.
†
Excludes non-users of glucocorticoids.
‡
In patients with antineutrophil cytoplasmic antibody-associated vasculitis only.